Cagrilintide Peptide Research: Long-Acting Amylin Receptor Agonism, Calcitonin Receptor Pharmacology, and Preclinical Body Weight Data

Cagrilintide is a long-acting amylin analog that acts as a non-selective agonist at amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor, signaling in the area postrema and hypothalamus to suppress food intake in preclinical models. Its defining feature is a C20 fatty diacid acylation that extends the elimination half-life to roughly 180 hours, compared with about 15 minutes for native amylin. In a RAMP1/3 knockout mouse study, cagrilintide lowered body weight by 3.4 g in wild-type animals but lost its effect when the receptors were deleted, establishing AMY1R and AMY3R as the required targets.

This article reviews the receptor pharmacology, structural chemistry, and preclinical body weight data behind cagrilintide peptide research. Cagrilintide, also designated AM833 and NN9838, has become one of the most studied amylin-class research compounds because it solved the aggregation problem that made earlier amylin peptides difficult to work with. For laboratories sourcing reference material, every Maple Research Labs compound ships with independent third-party verification through Janoshik Analytical certificates of analysis.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

What Is Cagrilintide and Why Does the Amylin Backbone Matter

Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. Native human amylin is notoriously unstable in solution because it aggregates into amyloid fibrils, the same class of structure implicated in islet pathology. This fibrillation makes native amylin nearly useless as a research tool, since the peptide degrades and precipitates before meaningful receptor work can be done. Pramlintide, an earlier analog, addressed aggregation by substituting three proline residues but retained a very short half-life of roughly 50 minutes.

Cagrilintide was engineered to keep the anti-aggregation benefits of a pramlintide-like scaffold while adding the metabolic stability needed for sustained receptor occupancy. Kruse and colleagues described the full development program in the Journal of Medicinal Chemistry in 2021. The peptide is built on a 37-residue amylin backbone with three principal substitutions, commonly described as N14E, V17R, and P37Y, which together suppress fibrillation and tune receptor activity. The most consequential modification is N-terminal acylation with a C20 eicosanedioic fatty diacid attached through a gamma-glutamic acid linker.

Cagrilintide Receptor Pharmacology

Amylin receptors are not single proteins. They are heterodimeric complexes formed when the calcitonin receptor associates with one of three receptor activity-modifying proteins, or RAMPs. Pairing the calcitonin receptor with RAMP1 produces AMY1R, with RAMP2 produces AMY2R, and with RAMP3 produces AMY3R. Cagrilintide is non-selective across this family and also activates the bare calcitonin receptor itself, which distinguishes it pharmacologically from more selective amylin analogs.

In the foundational pharmacology characterization, AM833 was profiled against six selective and non-selective agonists across the calcitonin receptor family. The compound showed binding affinity in the picomolar range, with reported binding IC50 values near 170 pM at the human AMY3R and 223 pM at the human calcitonin receptor. Functional cAMP accumulation assays returned EC50 values of approximately 348 pM at hAMY3R and 287 pM at hCTR, confirming that cagrilintide is a potent agonist at both the amylin-type and calcitonin-type complexes. This dual amylin and calcitonin receptor engagement is the mechanistic basis for the appetite-suppression signaling observed in animal models, since both receptor populations are expressed in the hindbrain area postrema where satiety signals are integrated.

The Acylation Chemistry Behind the Extended Half-Life

The single most important property of cagrilintide for sustained research applications is its half-life. Native human amylin has an elimination half-life of roughly 15 minutes, and pramlintide extends that only to about 50 minutes. Cagrilintide reaches an elimination half-life of approximately 159 to 195 hours, centering near 180 hours, a more than thousand-fold improvement over the parent hormone.

This extension comes from the C20 fatty diacid. The lipid chain promotes reversible binding to circulating albumin, creating a depot that slowly releases free peptide and shields it from rapid renal clearance and enzymatic degradation. This is the same albumin-binding principle used in other long-acting acylated peptides, and it is the reason cagrilintide can be studied with once-weekly administration schedules in animal models rather than continuous infusion. The structural and dynamic features of how cagrilintide engages the calcitonin and amylin receptor complexes were further detailed in cryo-EM and molecular dynamics work, which mapped the binding pose of the acylated peptide within the receptor binding pocket.

Key Research Findings

• Cagrilintide binds human AMY3R with an IC50 of approximately 170 pM and the human calcitonin receptor at approximately 223 pM, with cAMP EC50 values of 348 pM and 287 pM respectively (AM833 pharmacology characterization).
• Elimination half-life is approximately 180 hours (range 159 to 195 hours), versus roughly 15 minutes for native amylin and 50 minutes for pramlintide.
• In RAMP1/3 knockout mice on a 23-week high-fat diet, wild-type animals treated with 3 nmol/kg cagrilintide reduced day-one food intake from 2.7 plus or minus 0.2 g to 1.2 plus or minus 0.1 g (P less than 0.0001), an effect absent in knockout animals.
• Wild-type cagrilintide-treated mice lost 3.4 plus or minus 0.51 g of body weight over the treatment period (P less than 0.005), demonstrating dependence on AMY1R and AMY3R.
• In Phase 2 clinical testing of the compound, monotherapy at 4.5 mg produced 10.8 percent weight reduction over 26 weeks.

Preclinical Body Weight Data

The clearest mechanistic evidence for how cagrilintide works comes from a genetic knockout study published in eBioMedicine. Researchers used mice lacking RAMP1 and RAMP3, the modifying proteins that build the AMY1R and AMY3R complexes. Male wild-type and knockout littermates were maintained on a high-fat diet for 23 weeks to establish diet-induced obesity, then treated for three weeks with either vehicle or 3 nmol/kg cagrilintide administered subcutaneously once daily.

In wild-type animals, cagrilintide produced a sharp drop in food intake during the first days of treatment. On day one, vehicle-treated mice consumed 2.7 plus or minus 0.2 g while cagrilintide-treated mice consumed only 1.2 plus or minus 0.1 g, a difference reaching P less than 0.0001. Body weight in wild-type cagrilintide animals fell by 3.4 plus or minus 0.51 g (P less than 0.005). The critical finding is what happened in the knockout group: with RAMP1 and RAMP3 deleted, cagrilintide failed to reduce food intake or body weight. This loss-of-function result is strong evidence that the brain amylin receptors AMY1R and AMY3R are necessary for cagrilintide’s metabolic effects, rather than the calcitonin receptor acting alone or non-specific mechanisms. For researchers comparing incretin-class and amylin-class mechanisms, this stands in contrast to the GLP-1 receptor pathway examined in our semaglutide peptide research overview.

How Cagrilintide Differs From Incretin Peptides

Much research peptide attention has centered on GLP-1 and dual GIP/GLP-1 receptor agonists, but amylin signaling is a mechanistically distinct satiety pathway. Where incretin peptides act primarily through the GLP-1 and GIP receptors to influence insulin secretion and central appetite circuits, cagrilintide engages the calcitonin receptor family and signals through area postrema neurons. In preclinical and clinical research the two mechanisms appear complementary, which is why cagrilintide has been studied alongside semaglutide as a combination. Researchers investigating receptor-level differences between these classes can compare the amylin data here with the dual-receptor pharmacology covered in our tirzepatide research analysis and the broader incretin comparisons in our semaglutide versus tirzepatide comparison.

Research Handling and Verification Considerations

Because cagrilintide is an acylated peptide with a lipid moiety, its analytical profile differs from simpler unmodified sequences. Identity and purity confirmation typically relies on reverse-phase HPLC paired with mass spectrometry, since the fatty diacid and gamma-glutamate linker add mass that must be confirmed against the theoretical value. Net peptide content and counterion analysis matter for accurate molarity calculations in receptor work, given that the picomolar potencies discussed above leave little tolerance for concentration error. Every batch sold through Maple Research Labs is verified by independent third-party testing, and the corresponding documentation is available through our certificates of analysis and documentation pages. Researchers can review the full catalog on our peptides page.

Summary

Cagrilintide is a long-acting amylin analog that engages amylin and calcitonin receptors with picomolar potency and achieves a roughly 180-hour half-life through C20 fatty diacid acylation and albumin binding. Knockout studies establish AMY1R and AMY3R as the receptors required for its preclinical effects on food intake and body weight, with wild-type mice showing a 3.4 g weight reduction that disappears when the receptors are deleted. As a research compound, cagrilintide offers a stable, well-characterized tool for studying amylin pathway pharmacology, distinct from the incretin receptor systems that dominate much of the current metabolic peptide literature.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. The information above summarizes published in-vitro and animal-model findings and does not describe or recommend human administration.